Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3361523 | International Journal of Antimicrobial Agents | 2006 | 5 Pages |
Abstract
Conventional amphotericin B has been the ‘gold standard’ for antifungal efficacy, but nephrotoxicity problems limit its clinical utility. In the late 1990s, three lipid-based formulations of amphotericin B were introduced, all of which offered comparable efficacy and reduced renal complications. However, to date, robust safety and comparative efficacy data have been sparse. This paper briefly reviews the available clinical data on amphotericin B lipid complex (ABLC). Also, in detail, it reviews the findings of Collaborative Exchange of Antifungal Research (CLEAR®), the most extensive dataset on systemic antifungal treatment with the lipid-based agent ABLC.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Pranatharthi Chandrasekar,